



Advance In Diabetes Patches For Non-Invasive Glucose Monitoring

Pratiksha Rajkumar Ravankole

Department Of Pharmaceutical Chemistry

Delight College Of Pharmacy Koregaon Bhima Pune – 412216

Karishma Deepak Kamble, Akshada Ransing, Prashant Rajendra Chandane

Bachelor Of Pharmacy

Delight College Of Pharmacy Koregaon Bhima Pune - 412216

ABSTRACT

Diabetes mellitus is a chronic metabolic disorder affecting millions worldwide. Continuous glucose monitoring (CGM) is essential for effective diabetes management. Traditional methods like finger-prick tests are invasive and often lead to poor patient compliance. In recent years, diabetes patches have emerged as a promising non-invasive alternative for glucose monitoring. The rising prevalence of diabetes mellitus globally underscores the urgent need for improved therapeutic approaches that enhance adherence, minimize side effects, and reduce patient burden. Transdermal patches, particularly those utilizing microneedle arrays and glucose-responsive materials are promising alternatives to traditional insulin injections and oral hypoglycemic agents. This paper reviews recent innovations in diabetes patches, including passive transdermal systems, microneedle-based delivery (solid, coated, and dissolving), and advanced “smart” glucose-responsive patches. It discusses their mechanisms, advantages, limitations, and status in preclinical and clinical development. Real-world trials demonstrate that transdermal insulin delivery methods can match or, in some cases, surpass subcutaneous injections in terms of glycemic control, safety, and patient preference. Challenges such as drug stability, dosing accuracy, cost, and regulatory approval persist. Future directions point to integration with biosensing, closed-loop systems, and novel materials to bring a new generation of patches into mainstream clinical use. This review explores the evolution, types, mechanisms, advantages, limitations, and future prospects of diabetes patches, highlighting their potential to revolutionize diabetes care. Glucose-responsive drug delivery systems can make it easier for people with diabetes to follow their treatment and keep their blood sugar under control. Although these systems still have some problems, finding ways to solve them will make them easier to use. This review shares new ideas that could help in creating better diabetes medicines in the future.

KEYWORD

Transdermal drug delivery, Diabetes patches, Smart insulin delivery, Advanced healthcare materials

INTRODUCTION

Diabetes mellitus, characterized by chronic hyperglycemia, requires regular monitoring to prevent complications. Conventional glucose monitoring techniques, though effective, are invasive and uncomfortable. The development of wearable diabetes patches offers a non-invasive, continuous, and user-friendly solution. These patches integrate biosensors, microfluidics, and wireless communication to provide real-time glucose data.

Diabetes mellitus, encompassing both type 1 (insulin-dependent) and type 2 (insulin-resistant, or insulin-needing) forms, continues to burden healthcare systems worldwide. Elevated blood glucose over long periods is linked to complications including cardiovascular disease, kidney failure, neuropathy, and retinopathy. Traditional management strategies include:

- Frequent subcutaneous insulin injections, which are painful, risk infections, and often lead to poor compliance.
- Oral antidiabetic medicines, which may cause gastrointestinal side effects, have variable absorption, and are not always sufficient.


Transdermal drug delivery systems offer a potential solution: non-invasive or minimally invasive, bypassing first-pass metabolism, possibly enabling sustained and controlled release, and improving patient comfort and adherence. Diabetes mellitus is a health problem where the body cannot use insulin properly or does not make enough of it. There are four main types: type 1 diabetes (T1D), type 2 diabetes (T2DM), gestational diabetes, and secondary diabetes. Type 2 diabetes is the most common type. It used to be called “adult-onset diabetes” or “non-insulin-dependent diabetes.” Common symptoms include needing to urinate often, feeling very hungry or thirsty, tiredness, and sometimes pain. If blood sugar stays high for a long time, it can cause serious health issues like eye damage (which may lead to blindness), kidney failure, nerve damage, foot problems (sometimes leading to amputation), and a dangerous condition called diabetic ketoacidosis. The main treatments for diabetes are insulin and blood sugar-lowering medicines such as metformin (guanidine group), sulfonylureas, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 analogs, as well as some herbal and traditional medicines. These medicines help lower blood sugar and reduce the risk of complications. Managing diabetes usually requires a combination of medicine, healthy lifestyle changes, and regular blood sugar monitoring. Since there is no permanent cure yet, people with diabetes often need lifelong treatment. Current research is focused on finding new medicines that make treatment easier and more effective.

TYPES OF DIABETES PATCHES

1. Electrochemical Patches

These patches use enzymatic reactions to detect glucose levels in interstitial fluid. Glucose oxidase is commonly employed to generate an electrical signal proportional to glucose concentration.

They are wearable devices that stick to the skin and work using tiny electrical and chemical signals. They are mainly used for monitoring health markers (like glucose, lactate, electrolytes) or for delivering drugs through the skin.



Examples:

- . Glucose-monitoring patches for diabetes.
- . Sweat-based lactate sensors for athletes.
- . Insulin delivery electrochemical patches

2. Optical Patches

Optical patches utilize fluorescence, infrared spectroscopy, or Raman spectroscopy to detect glucose. They offer high sensitivity and specificity but may be affected by skin pigmentation and ambient light. They are wearable skin patches that use light-based technology like fluorescence, infrared, or color change to check body conditions or deliver medicine.


Examples:

- . Fluorescent patches for glucose sensing.
- . Near-infrared patches for monitoring blood oxygen.
- . Light-activated insulin delivery patches

3. Microneedle-Based Patches

Microneedles painlessly penetrate the skin to access interstitial fluid. These patches combine the benefits of minimal invasiveness with accurate glucose sensing. The microneedles painlessly pierce the outer layer of the skin without reaching deep nerves.

They can deliver medicine like insulin or vaccines directly into the body. Some microneedle patches can also collect fluid from the skin for health monitoring.



Uses:

- . Delivery of insulin for diabetes.
- . Vaccination without injections.
- . Monitoring glucose or other biomarkers.
- . Cancer therapy and cosmetic treatments.


4. Sweat-Based Patches

Sweat contains glucose and other biomarkers. Sweat-based patches use biosensors to analyze sweat composition, offering a truly non-invasive monitoring method.

The patch collects tiny amounts of sweat from the skin.

Built-in sensors detect chemical or physical changes in sweat.

The data is sent to a device (like a smartphone) for real-time monitoring.



Uses:

- . Continuous glucose monitoring for diabetes.
- . Checking hydration and electrolyte balance in patients.

Examples:


- . Glucose-sensing sweat patches for diabetes.
- . Lactate-monitoring patches for athletes.
- . Hydration-tracking sweat patches.

MECHANISM OF ACTION

Diabetes patches typically consist of three components:

- Sensor Layer: Detects glucose using enzymatic or optical methods.
- Microfluidic Layer: Channels interstitial fluid or sweat to the sensor.
- Communication Module: Transmits data to a smartphone or monitoring device.

The integration of these components enables real-time, continuous glucose monitoring without the need for blood samples.



ADVANTAGES OF DIABETES PATCHES

Non-Invasive: Eliminates the need for finger-pricks.

- Continuous Monitoring: Provides real-time data.
- Non-Invasive: Eliminates the need for finger-pricks.
- Continuous Monitoring: Provides real-time data.
- Data Integration: Facilitates remote monitoring and data analysis.

- Improved patient compliance & comfort: fewer needle pricks, less pain, better usability. Many clinical trials show patients prefer transdermal/microneedle systems over traditional shots.
- Continuous / controlled drug release: smart patches with stimuli-responsive materials. can modulate release in response to glucose levels.
- Avoidance of first-pass hepatic metabolism: more consistent bioavailability

LIMITATIONS AND CHALLENGES

- Accuracy: Variability in interstitial fluid and sweat glucose levels.
- Skin Irritation: Prolonged use may cause allergic reactions.
- Cost: Advanced patches may be expensive.
- Calibration: Some patches require periodic calibration with blood glucose levels.

RECENT DEVELOPMENTS

Recent innovations include:

- Flexible Electronics: Enhances patch comfort and wearability.
- AI Integration: Improves data interpretation and predictive analytics.
- Closed-Loop Systems: Combines monitoring with insulin delivery.
- Biocompatible Materials: Reduces skin irritation and enhances sensor performance.

FUTURE PROSPECTS

- The future of diabetes patches lies in:
- Personalized Medicine: Tailoring patches to individual needs.
- Integration with Wearables: Combining patches with smartwatches and fitness trackers.
- Global Accessibility: Making patches affordable and available worldwide.
- Regulatory Approvals: Ensuring safety and efficacy through clinical trials.

CONCLUSION

Diabetes patches represent a significant advancement in non-invasive glucose monitoring. While challenges remain, ongoing research and technological innovations are poised to overcome these hurdles. With continued development, diabetes patches could become the standard for glucose monitoring, improving the quality of life for millions of patients.

The field of diabetes patches has advanced substantially. Microneedle-based delivery and glucose responsive materials now show promising preclinical and early clinical results.

Transdermal delivery methods have in many trials matched subcutaneous insulin in effectiveness, and often improve patient comfort and preference.

For true translation to broad clinical use, future work should emphasize:

- Rigorous clinical trials, larger sample sizes, and long-term safety data.
- Further miniaturization and cost-efficient manufacturing of smart patches.
- Integration with reliable glucose sensors and possibly wearable electronics for closed-loop control.
- Ensuring robustness in varied environmental conditions (heat, moisture, movement), and in diverse patient populations (age, skin types).

If these challenges are met, diabetes patches could revolutionize management by making insulin therapy is less burdensome and more precise, improving quality of life significantly.

With advances in science and technology, new glucose-responsive drug delivery systems are being developed for diabetes treatment. These systems are designed to release medicine automatically when blood sugar levels go up, using special glucose-sensitive materials such as GOx (glucose oxidase), PBA (phenylboronic acid), and Con A (concanavalin A).

The goal is to give people with diabetes a smarter and more accurate treatment that works only when needed. However, there are still challenges, such as making the materials safe, sensitive, reliable, and comfortable for long-term use. Right now, there isn't enough clinical evidence to fully prove their effectiveness in real patients. In the future, with more research, these systems could become more advanced-offering personalized care, flexibility, and even smart connectivity with devices. If successful, glucose-responsive patches or systems could make diabetes treatment easier, more effective, and help prevent serious complications.

REFERENCES

Wang, J. (2020). Wearable biosensors for non-invasive glucose monitoring. *Sensors*, 20(3), 1-15.

1.Kim, J., et al. (2021). Microneedle patches for continuous glucose monitoring. *Advanced Healthcare Materials*, 10(5), 2001234.

2.Lee, H., et al. (2022). Sweat-based glucose sensors: A review. *Biosensors and Bioelectronics*, 195, 113647.

3.Zhang, Y., et al. (2023). Optical glucose sensors for diabetes management. *Analytical Chemistry*, 95(2), 456-468.

4.Patel, M., et al. (2024). Integration of AI in wearable diabetes patches. *IEEE Transactions on Biomedical Engineering*, 71(4), 789-798.

5. Liu, J., Yi, X., Zhang, J., Yao, Y., Panichayupakaranant, P., & Chen, H. (2024). Recent Advances in the Drugs and Glucose-Responsive Drug Delivery Systems for the Treatment of Diabetes: A Systematic Review. *Pharmaceutics*, 16(10), 1343.
<https://doi.org/10.3390/pharmaceutics16101343>

6. Alsunaidi, B., Althobaiti, M., Tamal, M., & Almalki, N. (2021). A review of noninvasive optical systems for continuous blood glucose monitoring. *Sensors*, 21(20), 6820.

7. Zhang, Y., Xu, B., Lim, C., Nolan, R., & Lee, D. (2021). Wearable glucose monitoring and implantable drug delivery systems for diabetes management. *Advanced Healthcare Materials*, 10(15), 2100194.

8. Chen, X., Shen, D., Yu, H., & Wang, L. (2021). Microneedle patch prepared from a hydrogel by a mild method for insulin delivery. *ChemNanoMat*, 7(10), 1075–1084.

9. Yu, J., Zhang, Y., Ye, Y., et al. (2015). Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. *Proceedings of the National Academy of Sciences*, 112(27), 8260–8265.

10. Wang, Y., Wang, H., Zhu, X., Guan, Y., & Zhang, Y. (2020). Smart microneedle patches for rapid, painless transdermal insulin delivery. *Journal of Materials Chemistry B*, 8, 8039–8047.

11. Wang, S., et al. (2024). Glucose-responsive microneedle patch with high insulin loading capacity for prolonged glycemic control in mice and minipigs. *ACS Nano*, 18(4), 6351–6362.
12. Limenh, L. W., et al. (2024). Effectiveness, safety, and preference of transdermal insulin delivery: A systematic review. *Frontiers in Pharmacology*, 15, 719905.
1. Pal, S. (2025). Glucose-responsive materials for smart insulin delivery. *ACS Materials Au*, 5(1), 12–26.
9. Chellathurai, M. S. (2023). Biodegradable polymeric insulin microneedles – design and applications. *Journal of Drug Delivery Science and Technology*, 79, 104030.
10. Martínez-Navarrete, M., et al. (2024). Latest advances in glucose-responsive microneedle-based transdermal insulin delivery. *Advanced Drug Delivery Reviews*, 205, 115579.
11. Review of noninvasive continuous glucose monitoring in diabetics. (2023). *ACS Sensors*, 8(9), 2551–2565.
12. Nanomaterial-assisted wearable glucose biosensors for noninvasive real-time monitoring: Pioneering point-of-care and beyond. (2024). *Nano Materials Science*, 5(3), 445–465.
13. Wearable hydrogel patch with noninvasive, electrochemical glucose sensor for natural sweat detection. (2022). *Talanta*, 240, 123154.
14. Demir, B., Rosselle, L., Voronova, A., Pagneux, Q., & Gmyr, V. (2025). Innovative transdermal delivery of insulin using gelatin methacrylate-based microneedle patches in mice and minipigs. *Nanoscale Horizons*, 10, 115–127.
15. Hu, Y., et al. (2024). A wearable microneedle patch incorporating reversible sensing/feedback elements for glucose monitoring. *Biosensors and Bioelectronics*, 240, 115652.
16. He, Y., et al. (2024). Glucose-responsive insulin microneedle patches for long-term diabetes management. *Advanced Functional Materials*, 34, 2306584.
17. Noninvasive on-skin biosensors for monitoring diabetes mellitus. (2025).
18. Recent advancements in noninvasive glucose monitoring and closed-loop management systems for diabetes. (2022). *Journal of Materials Chemistry*.
19. A concise and systematic review on noninvasive glucose monitoring for potential diabetes management. (2022). *Biosensors*.
20. Noninvasive, transdermal, path-selective and specific glucose monitoring via a graphene-based platform. (2018). *Biosensors and Bioelectronics*.